AnalystsPeter WelfordPeter Welford's Stock Forecasts
AnalystsPeter Welford
Sectors:
Industries:
Analyst Ranking
Bottom 14%
#4752 out of 5491 analysts
Average Return
-11.86%
Win Rate
57%4 out of 7
Risk vs Reward
Poor
Good
Peter Welford's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Novartis AgNVS | +15.65% | $106.44 | $123.10 | 2024-07-02 - 2025-07-01 | Strong Buy |
Astrazeneca PLCAZN | +11.50% | $137.88 | $153.74 | 2023-09-25 - 2024-09-24 | Strong Buy |
Astrazeneca PLCAZN | +9.41% | $100.10 | $109.52 | 2021-03-16 - 2021-12-07 | Strong Buy |
Gsk PLCGSK | +1.94% | $38.21 | $38.95 | 2024-07-02 - 2025-07-01 | Strong Buy |
Peter Welford Analyst Color
Get additional color on Peter Welford's coverage of popular stocks
Peter Welford's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Gsk PLCGSK | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Novartis AgNVS | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Astrazeneca PLCAZN | 4 | Hold | N/A | N/A | Downgrades | 3 years ago |
Lakefront Biotherapeutics NvLKFT | 2 | Hold | $47.20 | N/A | Upgrades | 4 years ago |
Genmab AGMAB | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Barinthus Biotherapeutics PLCBRNS | 1 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 5 years ago |
Celgene CorpCELG | 2 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.